All articles tagged with #desmoid tumors
Parabilis Medicines priced an upsized $670 million IPO (33.5 million shares at $20) — the largest biotech listing on record — with an option to raise up to another $100 million; proceeds will fund zolucatetide, a Wnt/beta-catenin pathway inhibitor for desmoid tumors, plus expanded trials and other assets as Parabilis pursues a Nasdaq listing under the PBLS ticker.
The FDA has granted approval to Springworks Therapeutics for their drug Ogsiveo, making it the first treatment available for desmoid tumors, a localized cancer that affects soft tissue and muscle. Desmoid tumors, although non-metastatic, can cause significant pain and disability. Currently, there are no approved therapies for this condition, with doctors resorting to off-label treatments such as chemotherapy, targeted therapies, radiation, and surgery.
The FDA has approved Ogsiveo (nirogacestat) tablets as the first therapy for adult patients with progressing desmoid tumors, a rare type of non-cancerous tumor. Desmoid tumors can be locally aggressive and cause pain and decreased quality of life. Ogsiveo demonstrated significant improvement in progression-free survival and tumor shrinkage compared to placebo in clinical trials. Common side effects include diarrhea, ovarian toxicity, rash, and nausea. Ogsiveo received Priority Review, Fast Track, Breakthrough Therapy, and Orphan-Drug designations.